Expression of ER, PgR, HER-2, and Ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy
- 24 Downloads
Many studies have indicated that the response to therapy and the prognostic impact of a pathologic complete response after neoadjuvant treatment differ among breast cancer subtypes.
The aim of our study is to evaluate the effect of this treatment on the expression of estrogen and progesterone receptors, human epidermal growth hormone receptor 2 and Ki67 in breast cancer. We identified 125 patients.
The estrogen receptor modified its expression from positive to negative in 8% patients and from negative to positive in 22%; progesterone in 21% and in 37% cases. Median Ki-67 value was 20.9% at biopsy and 18% after, HER-2 status did not show a remarkable change before or after neoadjuvant chemotherapy (NACT). We have identified a significant reduction in Ki-67 expression levels after chemotherapy in patients with a pathologic response. Detection of pretreatment Ki-67 could identify patients most likely to benefit from NACT.
NACT can change the status of ER, PgR, and Ki-67 expression in patients with breast adenocarcinoma, but it did not exert a significant effect on HER-2 status; HER-2 amplification appears to be more stable. We have identified a prognostic role for a decreased expression of PgR and Ki-67 after preoperative chemotherapy in breast cancer patients.
KeywordsBreast cancer Neoadjuvant chemotherapy Estrogen receptor Progesterone receptor Human epidermal growth factor receptor 2 Ki67
We thank the CINBO Istitution (Consorzio interuniversitario per la Bio-Oncologia) for support and contribution to our study.
Compliance with ethical standards
Conflict of interest
The authors declare no conflict of interest.
- 2.American Cancer Society (2009) Breast cancer facts and figures 2007–2008 Atlanta: American Cancer Society. http://www.cancer.org/downloads/stt/bcff-final.pdf
- 3.Kaufmann M, von Minckwitz G, Mamounas EP et al (2012) Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol. 19:1508–1516. https://doi.org/10.1245/s10434-011-2108-2 CrossRefPubMedGoogle Scholar
- 8.Ge W, Yang B, Zuo W et al (2015) Evaluation of hormone receptor, human epidermal growth factor receptor-2 and Ki 67 with core needle biopsy and neoadjuvant chemotherapy effects in breast cancer patients. Thoracic Cancer. https://doi.org/10.1111/1759-7714.12133 CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Zhou X, Zhang J, Yun H et al. (2015) Alterations of biomarker profiles after neoadjuvant chemotherapy in breast cancer: tumor heterogeneity should be taken into consideration. Oncotarget 6: 36894–36902. 10.18632/oncotarget.5050.Google Scholar
- 17.Kim HS, Park S, Koo JS (2016) Risk factors associated with discordant Ki-67 levels between preoperative biopsy and postoperative surgical specimens in breast cancers. PLoS One 11(3):0151054. https://doi.org/10.1371/journal.pone.0151054.eCollection2016 CrossRefGoogle Scholar
- 18.Criscitiello C, Disalvatore D, De Laurentiis M et al (2014) High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal-B HER2 negative and node-positive breast cancer. Breast 23:69–75. https://doi.org/10.1016/j.breast.2013.11.007 CrossRefGoogle Scholar
- 21.Miglietta L, Morabito F, Provinciali N (2013) A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients. Eur J Surg Oncol 39(10):1046–1052. https://doi.org/10.1016/j.ejso.2013.06.024 CrossRefPubMedGoogle Scholar
- 23.Gianni L, Eiermann W, Semiglazov V et al (2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2 negative cohort. Lancet 375:377–384. https://doi.org/10.1016/S0140-6736(09)61964-4 CrossRefPubMedGoogle Scholar
- 27.Goldhirsch A, Winer EP, Coates AS et al (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24:2206–2223. https://doi.org/10.1093/annonc/mdt303 CrossRefPubMedPubMedCentralGoogle Scholar
- 29.Bossuyt V, Provenzano E, Symmans WF et al (2015) Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. Ann Oncol 26:1280–1291. https://doi.org/10.1200/JCO.2012.43.4134 CrossRefPubMedPubMedCentralGoogle Scholar
- 30.Provenzano E, Bossuyt V, Viale G et al (2015) Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. Mod Pathol 28:1185–1201. https://doi.org/10.1038/modpathol.2015.74 CrossRefPubMedPubMedCentralGoogle Scholar
- 34.Kurozumi S, Inoue K, Takei H et al (2015) ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab. BMC Cancer 15:622. https://doi.org/10.1186/s12885-015-1641-y CrossRefPubMedPubMedCentralGoogle Scholar
- 35.Valachis A, Mauri D, Polyzos NP, Chlouverakis G, Mavroudis D, Georgoulias V (2011) Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: a systematic review and meta-analysis. Breast 20(6):485–490. https://doi.org/10.1016/j.breast.2011.06.009 CrossRefPubMedGoogle Scholar
- 41.Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ (2011) Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol 2011 22:1736–1747. https://doi.org/10.1093/annonc/mdr304.CrossRefGoogle Scholar
- 45.Viale G, Giobbie-Hurder A, Regan MM et al (2008) Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1–98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 26(34):5569–5575. https://doi.org/10.1200/JCO.2008.17.0829 CrossRefPubMedPubMedCentralGoogle Scholar